The AIDS Malignancy Consortium (AMC) is an NCI-supported clinical trials group founded in 1995 to support innovative trials for HIV-associated malignancies. The AMC is now composed of eight Domestic Core Sites and a number of affiliated sites that contribute patients to domestic AMC trials. The AMC is committed to enhancing therapeutic options for patients with HIV-associated malignancies.